Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
ECDD Technical summary
3,4,5-Trimethoxyamphetamine (3,4,5-TMA) is a racemic mixture with a similar pharmacological profile to that of LSD, with some amphetamine-like activity in the "spinal dog’. It is cross-tolerant with LSD. No toxicological data are available. In rodents 3,4,5-trimethoxyamphetamine produces discriminative effects similar to those of 2,5-dimethoxy-a,4-dimethylbenzeneethanamine (DOM) another known hallucinogen of this series. No clinical abuse data are available, and the nature and magnitude of associated public health or social problems are unknown. No information is available on the epidemiology of its use and abuse. The substance is under national control in several countries. There is no known therapeutic use for the substance and thus no lawful production. Seizures of the drug and the discovery of a number of clandestine laboratories indicate that there is illicit trafficking in the substance in Canada and the United States of America. On the basis of the data outlined above, it was the consensus of the Expert Committee that 3,4,5-trimethoxyamphetamine met the
criteria in article 2, paragraph 4, for control under the Convention on Psychotropic Substances. Since it has no known clinical use, the Expert Committee recommended that it be placed in Schedule I of the Convention.
3,4,5-Trimethoxyamphetamine (3,4,5-TMA) is a racemic mixture with a similar pharmacological profile to that of LSD, with some amphetamine-like activity in the "spinal dog’. It is cross-tolerant with LSD. No toxicological data are available. In rodents 3,4,5-trimethoxyamphetamine produces discriminative effects similar to those of 2,5-dimethoxy-a,4-dimethylbenzeneethanamine (DOM) another known hallucinogen of this series. No clinical abuse data are available, and the nature and magnitude of associated public health or social problems are unknown. No information is available on the epidemiology of its use and abuse. The substance is under national control in several countries. There is no known therapeutic use for the substance and thus no lawful production. Seizures of the drug and the discovery of a number of clandestine laboratories indicate that there is illicit trafficking in the substance in Canada and the United States of America. On the basis of the data outlined above, it was the consensus of the Expert Committee that 3,4,5-trimethoxyamphetamine met the
criteria in article 2, paragraph 4, for control under the Convention on Psychotropic Substances. Since it has no known clinical use, the Expert Committee recommended that it be placed in Schedule I of the Convention.
ECDD Recommendation
Inclusion in Schedule I of the 1971 Convention on Psychotropic Substances
Link to full TRS
who_trs_729.pdf1.29 MB